Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

2012 ◽  
Vol 48 (17) ◽  
pp. 3223-3231 ◽  
Author(s):  
Seok Jin Kim ◽  
Dok Hyun Yoon ◽  
Hye Jin Kang ◽  
Jin Seok Kim ◽  
Seong Kyu Park ◽  
...  
Keyword(s):  
T Cell ◽  
Stage Iii ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Trial ◽  
T Cell Lymphomas ◽  
Peripheral T Cell Lymphomas ◽  
First Line Treatment

scholarly journals Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas

Hematology ◽  
2016 ◽  
Vol 21 (9) ◽  
pp. 536-541 ◽  
Author(s):  
Bo Jia ◽  
Shaoxuan Hu ◽  
Jianliang Yang ◽  
Shengyu Zhou ◽  
Peng Liu ◽  
...  
Keyword(s):  
T Cell ◽  
Line Treatment ◽  
First Line ◽  
T Cell Lymphomas ◽  
Peripheral T Cell Lymphomas ◽  
First Line Treatment

scholarly journals Uveitis and Myositis as Immune Complications in Chemorefractory NK/T-Cell Nasal-Type Lymphoma Successfully Treated with Allogeneic Stem-Cell Transplant

2016 ◽  
Vol 2016 ◽  
pp. 1-5
Author(s):  
Maria José Gómez-Crespo ◽  
Aránzazu García-Raso ◽  
Jose Luis López-Lorenzo ◽  
Teresa Villaescusa ◽  
María Rodríguez-Pinilla ◽  
...  
Keyword(s):  
T Cell ◽  
Lower Limbs ◽  
Manuscript Preparation ◽  
Cell Transplant ◽  
Line Treatment ◽  
First Line ◽  
Inflammatory Myositis ◽  
T Cell Lymphomas ◽  
Nk T Cell ◽  
First Line Treatment

NK/T-cell lymphomas are a group of clonal proliferations of NK- or, rarely, T-cell types and have peculiar clinicopathologic features. Most common site of involvement is the upper aerodigestive tract (nasal cavity, nasopharynx, paranasal sinuses, and palate). Association of autoimmune paraneoplastic disorders with NK/T-cell lymphomas is not well studied. Our patient was diagnosed with NK/T-cell lymphoma stage IV with skin involvement and treated frontline with CHOEP regimen. While he was under treatment, two immune complications presented: anterior uveitis of autoimmune origin refractory to steroids and myositis in lower limbs muscles. Autologous transplantation was rejected due to confirmed early relapse after first-line treatment, and the patient received second-line treatment according to the SMILE scheme, reaching complete response after four cycles. The patient underwent allogeneic transplantation and at the time of manuscript preparation is alive despite multiple complications. The disease should be suspected in patients with rhinitis or recurrent sinusitis, and early biopsy is recommended for all patients to avoid a delay in diagnosis. Our patient also presented symptoms of disease progression after first-line treatment, representing a paraneoplastic process, a very rare phenomenon in T-type lymphomas. This case is novel for the appearance of an inflammatory myositis, a histologically verified paraneoplastic phenomenon that responded to treatment for lymphoma.

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

2010 ◽  
Vol 11 (9) ◽  
pp. 845-852 ◽  
Author(s):  
Gianluca Masi ◽  
Fotios Loupakis ◽  
Lisa Salvatore ◽  
Lorenzo Fornaro ◽  
Chiara Cremolini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Trial ◽  
First Line Treatment

Predictors of disease control in patients treated with platinum-based chemotherapies for metastatic squamous-cell esophageal cancer: First results of the e-DIS trial.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 95-95
Author(s):  
Antoine Adenis ◽  
Jaafar Bennouna ◽  
Marie-Pierre Galais ◽  
Emmanuelle Tresch ◽  
Eric Francois ◽  
...  
Keyword(s):  
Disease Control ◽  
Bone Metastases ◽  
Metastatic Disease ◽  
Disease Assessment ◽  
Concomitant Disease ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Trial ◽  
First Line Treatment

95 Background: There is little evidence that chemotherapy (CT) impacts on outcome of patients with MSEC. We designed an ongoing randomized phase 2 trial to detect a progression-free survival benefit of CT continuation over CT discontinuation in disease-controlled and ECOG≤2 patients at 6 weeks after an initial CT treatment. The aim of the present study was to identify predictors of disease control at 6 weeks (DC6wkx) in MSEC patients receiving platinum-based CTs as first-line treatment for metastatic disease. Methods: Among 68/70 evaluable patients included between 1/2011 and 7/2013 who received at least 1 CT cycle, 58 were evaluable for disease assessment at 6 weeks. Ten patients were not evaluable (early death: 4, patient’s decision: 2, concomitant disease 1, early progressive disease 1, other reasons: 2). Baseline demographic, clinical, biological, and tumor characteristics were tested for prediction of DC6wkx. Significant variables for DC6wkx were identified with the chi-squared test and logistic regression. Results: Baseline patients characteristics were as follows: median age: 61.5yo; male: 57/68; ECOG 0/1/2: 13/42/13; metachronous/synchronous MSEC: 38/30; number of metastatic sites 1/2/>2: 35/20/13; metastatic location: lung 36, liver 23, bone 11, nodes 37, other 11; prior exposure to CT: 37/68; time from previous CT exposure: ≤ 6m 6/37, 6-12m 14/37, > 12m 17/37; gr>2 dysphagia (Atkinson) 19/67; BMI<18.5kg/m²: 13/68. Current CTs were FU-CDDPq3w 2/68, LV5FU2-CDDPq2w 15/68, FOLFOX 51/68, and patients received the following number of cycles 1/2/>2: 5/7/54. DC6wkx rate was 65.7%, with 16/68 PR (23.5%) and 28/68 SD (42.2%). Albumin (p<0.01), BMI (p<0.02), bone metastases (p<0.005), gender (p<0.047) and ECOG status (p<0.05) were predictive of DC6wkx. Normal or overweight BMI, grade 0 albumin, and no bone metastases, were predictive of DC6wkx in multivariate analysis. Conclusions: DC at 6 wks was 65.7% in MSEC receiving platinum-based CTs as first line treatment for metastatic disease. Normal or overweight BMI, normal albumin, and the absence of bone metastasis were significant predictors of DC6wkx in this prospective phase 2 trial. Clinical trial information: NCT01248299.

Sign in / Sign up

Export Citation Format

Share Document